reports
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” -White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and id...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuin...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Heal...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco. The live event and replay of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ live...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in t...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the . ACSL5 is an enz...
Capital Southwest Corporation Announces the Promotion of Grant Eason t...
Capital Southwest Corporation Announces the Promotion of Grant Eason to Managing Director DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses is pleased to announce the promotion of Grant Eason to Managing Director. “I am pleased to announce the promotion of Grant Eason to Managing Director,” stated Josh Weinstein, Chief Investment Officer of Capita...
Greene County Bancorp, Inc. Recognized as a Top-Performing Bank in Pip...
Greene County Bancorp, Inc. Recognized as a Top-Performing Bank in Piper Sandler’s Class of 2025 Bank & Thrift Small-Cap All Stars CATSKILL, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for the Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported inclusion into Piper Sandler’s Class of 2025 Sm-All Stars, an honor recognizing top-performing banks in the small cap segment. The Company ranked 9th out of 24 recognized banks and thrifts and has been included on the list a total of nine ...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in No...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-...
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
MSBI MIDLAND STATES BANCORP
WMG WARNER MUSIC GROUP CORP.
IIIV I3 VERTICALS
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
SPT SPROUT SOCIAL
BMEA INC.
PBBK BIOMEA FUSION
NRDY INC.
MAIA PB BANKSHARES
SMRT INC.
SPRU NERDY INC.
BAER MAIA BIOTECHNOLOGY INC
SGI SMARTRENT INC
GF SPRUCE POWER HOLDING CORP
AFCG WILDFIRE NEW PUBCO
KITT INC.
SOMNIGROUP INTERNATIONAL INC.
THE NEW GERMANY FUND
INC.
AFC GAMMA
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
- Jonathan Moreland
Lexicon Pharmaceuticals to Participate in Two Upcoming December Invest...
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceutic...
- Jonathan Moreland
PPSI PIONEER POWER SOLUTIONS
PEB PEBBLEBROOK HOTEL TRUST
PCTY PAYLOCITY HOLDING CORP.
OPK OPKO HEALTH INC.
LOB LIVE OAK BANCSHARES
GOGO GOGO INC.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
FAST FASTENAL COMPANY
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNS COHEN & STEERS INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
INTT INTEST CORP.
MIRM MIRUM PHARMACEUTICALS
TSLX SIXTH STREET SPECIALTY LENDING
MYPS INC.
QDEL PLAYSTUDIOS INC
GTE QUIDEL CORP
ET GRAN TIERRA ENERGY INC.
MXF ENERGY TRANSFER LP
GDV THE MEXICO FUND
INC.
THE GABELLI DIVIDEND & INCOME TRUST
Capital Southwest Announces Monthly Regular Dividends for the Quarter ...
Capital Southwest Announces Monthly Regular Dividends for the Quarter Ending March 31, 2026 and Quarterly Supplemental Dividend Payable on March 31, 2026 DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce that its Board of Directors has declared monthly regular dividends of $0.1934 per share for each of January, February and M...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
FOXF FOX FACTORY HOLDING CORP.
FLDM FLUIDIGM
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
TREX TREX COMPANY INC.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
HFFG HF FOODS GROUP INC
AVTR AVANTOR
PGNY INC.
TELA PROGYNY
SMCI TELA BIO
MRVI SUPER MICRO COMPUTER
BLND INC.
BHVN MARAVAI LIFESCIENCES HOLDINGS
DRCT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
VANI BIOHAVEN LTD
GTE DIRECT DIGITAL HLDGS INC
GT VIVANI MEDICAL INC
CRVO GRAN TIERRA ENERGY INC.
NCDL GOODYEAR TIRE & RUBBER CO.
NEXT CERVOMED INC
CATX NUVEEN CHURCHILL DIRECT LENDING CORP
RMI NEXTSOURCE MATERIALS INC.
BATRK PERSPECTIVE THERAPEUTICS
GMRE INC.
RIVERNORTH OPPOR MUN INC FD INC
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
RGP RESOURCES CONNECTION INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
FDS FACTSET RESEARCH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
GAM GENERAL AMERICAN INVESTORS CO. INC.
WHF WHITEFIELD
FMC FMC CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
ITGR INTEGER HOLDINGS CORPORATION
ICHR ICHOR HOLDINGS LTD.
KREF KKR REAL ESTATE FINANCE TRUST
NWPP NEW PEOPLES BANKSHARES INC.
REZI RESIDEO TECHNOLOGIES
WU INC.
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
BW AMCOR PLC
THRY BABCOCK & WILCOX ENTERPRISES
UTZ THRYV HOLDINGS
OPEN UTZ BRANDS INC (A)
ACVA OPENDOOR TECHNOLOGIES INC.
UPST ACV AUCTIONS INC.
FRSH UPSTART HOLDINGS
CLVT FRESHWORKS INC.
TRDA CLARIVATE PLC
SG ENTRADA THERAPEUTICS INC
TBBK SWEETGREEN INC
BLND THE BANCORP
CRVO INC.
NEXT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
SPRU CERVOMED INC
LAW NEXTSOURCE MATERIALS INC.
MRAI SPRUCE POWER HOLDING CORP
BNTC CS DISCO INC
GF MARPAI
HYMC INC.
SENS BENITEC BIOPHARMA INC
BATRK THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
- Jonathan Moreland
BLMN BLOOMIN' BRANDS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
DLY LYONDELLBASELL INDUSTRIES NV
KMPR KEMPER CORPORATION
GOOD GLADSTONE COMMERCIAL CORPORATION
FLDM FLUIDIGM
CROX CROCS INC.
ASA ASA
AROW ARROW FINANCIAL CORP.
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
REZI RESIDEO TECHNOLOGIES
FSK INC.
WU FS KKR CAPITAL CORP
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
AIMD.P AMCOR PLC
DKNG AIM4 VENTURES
OPEN DRAFTKINGS INC
ACVA OPENDOOR TECHNOLOGIES INC.
FRSH ACV AUCTIONS INC.
TRDA FRESHWORKS INC.
SG ENTRADA THERAPEUTICS INC
FRST SWEETGREEN INC
BLND PRIMIS FINANCIAL CORP
GTE ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
LAW GRAN TIERRA ENERGY INC.
MRAI CS DISCO INC
GF MARPAI
RMI INC.
THE NEW GERMANY FUND
INC.
RIVERNORTH OPPOR MUN INC FD INC
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London He...
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST). The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering med...
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Eje...
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sot...
- Jonathan Moreland
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
JBLU JETBLUE AIRWAYS CORPORATION
GBCI GLACIER BANCORP INC.
ASA ASA
TZOO TRAVELZOO
RLMD RELMADA THERAPEUTICS
NSC NORFOLK SOUTHERN CORPORATION
GCBC GREENE COUNTY BANCORP INC.
CSBR CHAMPIONS ONCOLOGY
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
CSBB C S B BANCORP OHIO
AVO MISSION PRODUCE
TDUP THREDUP INC.
NVCT NUVECTIS PHARMA INC
BPRN BANK OF PRINCETON
GTE GRAN TIERRA ENERGY INC.
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results a...
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas,...
Standard BioTools Reports Third Quarter 2025 Financial Results
Standard BioTools Reports Third Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025. Recent Highlights: Third quarter 2025 total combined company revenue of $46.2 million; Revenue from continuing operations of $19.6 millionImplemented restructuring plan expected to deliver over $40 million in annualized cost savings; On track to achieve positive adjusted EBITDA target in 2026$217.0 million in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.